Literature DB >> 2766506

Influence of mitral valve morphology on double-balloon catheter balloon valvuloplasty in patients with mitral stenosis. Analysis of factors predicting immediate and 3-month results.

C L Reid1, P A Chandraratna, D T Kawanishi, A Kotlewski, S H Rahimtoola.   

Abstract

To determine if mitral valve morphology influences the results of double-balloon catheter balloon valvuloplasty (CBV) for mitral stenosis, two-dimensional echocardiography was performed in 33 patients before CBV. The two-dimensional echocardiographic features of leaflet motion, leaflet thickness, subvalvular disease, and commissural calcium and 14 pre-CBV clinical and hemodynamic variables were then correlated to the immediately post-CBV mitral valve area (MVA). At 3 months after CBV, the two-dimensional echocardiographic features of patients with a 25% or greater decrease in MVA were analyzed to determine whether mitral valve morphology had influenced early results. Leaflet motion had a significant relation with the immediately post-CBV MVA (r = 0.67, y = 4.5x + 0.29, and SEE = 0.45). Leaflet thickness had a weak and negative relation (r = -0.48, y = -0.17x + 2.6, and SEE = 0.53) with the immediately post-CBV MVA. Subvalvular disease and commissural calcium had no significant relation to the immediately post-CBV MVA. When leaflet motion and leaflet thickness were considered as grades of mild, moderate, and severe and assigned a score of 0-2, patients with more severe disease (total score, 3 or 4) had a significant lower MVA immediately after CBV (1.4 +/- 0.4 cm2) than patients with moderate disease (score, 1-2; MVA, 2.0 +/- 0.5 cm2; p less than 0.05) or mild disease (score, 0; MVA, 2.6 +/- 0.6 cm2; p less than 0.05). In 96% of patients with a total score of 0-2, the immediately post-CBV MVA was more than 1.4 cm2, whereas only 29% of patients with a total score of 3-4 had an immediately post-CBV MVA of more than 1.4 cm2. Analysis of all two-dimensional echocardiographic features showed that leaflet motion score had the strongest influence on the post-CBV MVA (p less than 0.001). When all two-dimensional echocardiographic, clinical, and hemodynamic variables were included, leaflet motion, effective balloon dilating area, and cardiac output were the strongest predictors of the immediate post-CB MVA.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2766506     DOI: 10.1161/01.cir.80.3.515

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

Review 1.  Percutaneous mitral balloon valvuloplasty.

Authors:  C E Mayes; J E Cigarroa; R A Lange; L D Hillis
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

2.  The predictive value of mitral leaflet motion and thickness index scores on early restenosis after mitral balloon valvuloplasty.

Authors:  Mustafa Akin; Abdi Sagcan; Sanem Nalbantgil; Filiz Ozerkan; Azem Akilli; Yavuzgil Oguz; Mehdi Zoghi
Journal:  Tex Heart Inst J       Date:  2004

3.  Predictors of event-free survival after percutaneous mitral commissurotomy.

Authors:  N Meneveau; F Schiele; M F Seronde; V Breton; S Gupta; Y Bernard; J P Bassand
Journal:  Heart       Date:  1998-10       Impact factor: 5.994

4.  New Scores for the Assessment of Mitral Stenosis Using Real-Time Three-Dimensional Echocardiography.

Authors:  Osama I I Soliman; Ashraf M Anwar; Ahmed K Metawei; Jackie S McGhie; Marcel L Geleijnse; Folkert J Ten Cate
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-07-09

5.  Stepwise Protocols for Scoring of Mitral Valve using Three-Dimensional Transthoracic Echocardiography in Mitral Stenosis.

Authors:  Ashraf M Anwar; Wael M Attia
Journal:  J Cardiovasc Echogr       Date:  2019 Jan-Mar

6.  Echocardiographic assessment of mitral valve morphology after Percutaneous Transvenous Mitral Commissurotomy (PTMC).

Authors:  Hosam Hasan-Ali; Hamdy Shams-Eddin; Alaa A Abd-Elsayed; Muhammad H Maghraby
Journal:  Cardiovasc Ultrasound       Date:  2007-12-08       Impact factor: 2.062

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.